by Investec Switzerland. Novartis AG employees in Shanghai have a new billion home. The seven-building campus on the outskirts of Shanghai is accented by bamboo staircases and tree-lined courtyards. The company said the 1,300-person facility will be its third major research center, after Basel, Switzerland, and Cambridge, Massachusetts. © Sean Pavone | Dreamstime.com Foreign drugmakers are investing in China because of surging demand for medicines as the incidence of chronic conditions like cancer, heart disease and diabetes rise. The government has provided incentives to encourage more investment in innovation, while Chinese consumers are spending more on health care as their incomes rise. “The commitment that Novartis is making in China is bigger than anybody else in the industry,” Chief Executive Officer Joe Jimenez said in an interview. “We expect Shanghai to ramp up relatively quickly” in terms of drug discovery. The Novartis research center will further focus on diseases more prevalent in China, such as lung, liver and gastric cancer. Having new medicines in those areas in coming years will help the Basel-based company to secure a toehold in the world’s second-largest pharmaceutical market after the U.S. By Bloomberg News (Bloomberg) Facebook and Twitter.
Topics:
Investec considers the following as important: Business & Economy, Novartis in China, Novartis in Shanghai
This could be interesting, too:
Investec writes Swiss National Bank to issue new money
Investec writes Swiss want more political action on immigration
Investec writes Swiss Rail financial results disappoint
Investec writes Swiss economy grows more than expected in second quarter of 2024
Novartis AG employees in Shanghai have a new $1 billion home. The seven-building campus on the outskirts of Shanghai is accented by bamboo staircases and tree-lined courtyards. The company said the 1,300-person facility will be its third major research center, after Basel, Switzerland, and Cambridge, Massachusetts.
© Sean Pavone | Dreamstime.com
Foreign drugmakers are investing in China because of surging demand for medicines as the incidence of chronic conditions like cancer, heart disease and diabetes rise. The government has provided incentives to encourage more investment in innovation, while Chinese consumers are spending more on health care as their incomes rise.
“The commitment that Novartis is making in China is bigger than anybody else in the industry,” Chief Executive Officer Joe Jimenez said in an interview. “We expect Shanghai to ramp up relatively quickly” in terms of drug discovery. The Novartis research center will further focus on diseases more prevalent in China, such as lung, liver and gastric cancer. Having new medicines in those areas in coming years will help the Basel-based company to secure a toehold in the world’s second-largest pharmaceutical market after the U.S.
By Bloomberg News (Bloomberg)